Current status of adjuvant bisphosphonates in operable breast cancer

Bisphosphonates offer a potentially effective adjuvant therapy to reduce recurrence of bone metastases in breast cancer patients. Clinical trials are at the early stage, but initial results have shown promise. There are three published adjuvant trials of oral clodronate, and one trial each of pamidr...

Full description

Saved in:
Bibliographic Details
Published inBreast cancer online Vol. 11; no. 4; p. e7
Main Author Paterson, A. H. G.
Format Journal Article
LanguageEnglish
Published Cambridge, UK Cambridge University Press 01.04.2008
Subjects
Adjuvant therapy
Bisphoshonates
Bone metastases
Online AccessGet full text

Cover

More Information
Summary:Bisphosphonates offer a potentially effective adjuvant therapy to reduce recurrence of bone metastases in breast cancer patients. Clinical trials are at the early stage, but initial results have shown promise. There are three published adjuvant trials of oral clodronate, and one trial each of pamidronate and zoledronic acid. Observed complications so far include osteonecrosis of the jaw or maxilla because bisphosphonates inhibit bone turnover, as well as renal toxicity. Thus, care needs to be taken with dosage and duration of treatment and patients carefully managed.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1470-9031
1470-9031
DOI:10.1017/S1470903108004343